International Stem Cell Corporation
International Stem Cell Corporation (ISCO), headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in stem cell research and regenerative medicine. Founded in 2007, ISCO has made significant strides in developing innovative therapies and products, particularly in the fields of cell therapy and human therapeutic applications. The company is renowned for its unique human parthenogenetic stem cell technology, which offers a promising alternative to traditional stem cell sources. ISCO's core products include stem cell lines and related research tools, which are designed to advance scientific understanding and therapeutic potential. With a strong market position, ISCO has achieved notable milestones, including collaborations with leading research institutions and advancements in clinical applications, solidifying its reputation as a leader in the stem cell sector.
DitchCarbon Score
How does International Stem Cell Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
International Stem Cell Corporation's score of 26 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
International Stem Cell Corporation's reported carbon emissions
In 2023, International Stem Cell Corporation (ISCC) reported total carbon emissions of approximately 2,585,100 kg CO2e across all scopes. This includes 2,585,100 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 2,585,100 kg CO2e from Scope 2 emissions, which are indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions were also reported at 2,585,100 kg CO2e, with significant contributions from business travel, amounting to 657,630 kg CO2e. Despite these figures, ISCC has not established specific reduction targets or initiatives as part of their climate commitments. There are no climate pledges or SBTi (Science Based Targets initiative) targets reported, indicating a potential area for future development in their sustainability strategy. The emissions data is not cascaded from any parent or related organization, and all reported figures are directly attributed to International Stem Cell Corporation. As the company continues to operate within the biotechnology sector, addressing carbon emissions and setting reduction targets will be crucial for aligning with industry standards and expectations regarding climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 2,585,100 |
| Scope 2 | 2,585,100 |
| Scope 3 | 2,585,100 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
International Stem Cell Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
